AbbVie, Inc. (NYSE:ABBV) announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis. AbbVie Inc (NYSE:ABBV) stock performance was 1.07% in last session and finished the day at $53.68. The average volume of the stock remained 6.26million shares. AbbVie Inc (NYSE:ABBV) insider ownership is 0.10%.
NeoStem, Inc. (Nasdaq:NBS) announced that, on March 11, 2014, the Data Safety Monitoring Board (“DSMB”) recommended continuing the PreSERVE AMI Phase 2 clinical trial following a fourth interim data and safety review. The PreSERVE trial of AMR-001 is a Phase 2, randomized, placebo controlled, double-blind study designed to enroll 160 patients. NeoStem Inc (NASDAQ:NBS) dropped -0.97 percent to $7.18. The intra-day range of the stock was $7.10 to $7.36. NeoStem Inc (NASDAQ:NBS) has a market capitalization of $205.22million.
Occidental Petroleum Corp. (NYSE:OXY) shares dropped 2.5%. Occidental said recently that it plans to split its California operations into a separate, publicly traded company. Occidental Petroleum Corporation (NYSE:OXY)’s stock on Mar 20, 2014 reported a decrease of -2.32% to the closing price of $92.93. Its fifty two weeks range is $77.21 -$99.42. The total market capitalization recorded $73.86billion. The overall volume in the last trading session was 10.00million shares. In its share capital, OXY has 802.00million outstanding shares.
Wells Fargo & Co. (NYSE:WFC) saw some unusual options trading on Thursday. Stock investors acquired 17,010 put options on the company, AR Network reports. This represents an increase of approximately 166% compared to the typical daily volume of 6,391 put options. On Thursday, shares of Wells Fargo & Co (NYSE:WFC) advanced 2.55% to close the day at $49.03. Company return on investment (ROI) is 9.80% and its monthly performance is recorded as 7.69%. Wells Fargo & Co (NYSE:WFC) quarterly revenue growth is 13.23%.